Last Updated: June 22, 2026

Patent: 8,992,926

✉ Email this page to a colleague

Summary for Patent: 8,992,926

Title:	Methods of administering anti-TNFα antibodies
Abstract:	Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K=10M or less), a slow off rate for hTNFα dissociation (e.g., K=10secor less) and neutralize hTNFα activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
Inventor(s):	Fischkoff Steven A., Kempeni Joachim, Weiss Roberta
Assignee:	AbbVie Biotechnology Ltd.
Application Number:	US14498952
Patent Claims:	see list of patent claims

Details for Patent 8,992,926

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	December 31, 2002	8,992,926	2034-09-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	February 21, 2008	8,992,926	2034-09-26
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	April 24, 2013	8,992,926	2034-09-26
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,992,926

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Argentina	034429	⤷ Start Trial
Argentina	077572	⤷ Start Trial
Argentina	090099	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.